{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.99","upperLimit":"1.04","value":"1.00"}]}],"title":"Tmax at Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"2.00","value":"1.00"}]}],"title":"Tmax at Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Tmax at Days 1 and 29 was analyzed. Tmax is defined as the time of Cmax (the maximum concentration of drug).","dispersionType":"Inter-Quartile Range","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEAN","populationDescription":"Participants in the PK Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29","title":"PK Parameter: Tmax","type":"SECONDARY","unitOfMeasure":"hours"}